[1]刘 玲 刘德亮 李惠林* 赵恒侠 渠 听 李增英 张学文.活血降糖饮治疗2型糖尿病气阴两虚证30例[J].现代中医药,2017,(05):016-20.[doi:10.13424/j.cnki.mtcm.2017.05.007]
 Liu Ling,Liu Deliang,Li Huilin,et al.On Treatment of 30 Cases of Type 2 Diabetes with Qi-Yin Deficiency Syndrome by Huoxue Jiangtang Potion[J].Modern Traditional Chinese Medicine,2017,(05):016-20.[doi:10.13424/j.cnki.mtcm.2017.05.007]
点击复制

活血降糖饮治疗2型糖尿病气阴两虚证30例 ()
分享到:

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2017年05期
页码:
016-20
栏目:
临床研究
出版日期:
2017-09-10

文章信息/Info

Title:
On Treatment of 30 Cases of Type 2 Diabetes with Qi-Yin Deficiency Syndrome by Huoxue Jiangtang Potion
文章编号:
1672一0571(2017)05一0016一O5
作者:
刘 玲1 刘德亮1 李惠林1* 赵恒侠1 渠 听1 李增英1 张学文2
1.深圳市中医院,广东 深圳 518033;2.陕西中医药大学,陕西 咸阳 712046
Author(s):
Liu Ling1Liu Deliang1Li Huilin1Zhao Hengxia1Qu Xin1 Li Zengying1Zhang Xuewen2
1.Shenzhen Hospital of Chinese Medicine,Shenzhen 518033,China; 2.Shaanxi University of Chinese Medicine,Xianyang 712046,China
关键词:
活血降糖饮气阴两虚证2型糖尿病DPP-4活性
Keywords:
Huoxue Jiangtang potionqi-yin deficiency syndrometype 2diabetesDPP-4enzyme activity
分类号:
R255.4
DOI:
10.13424/j.cnki.mtcm.2017.05.007
文献标志码:
A
摘要:
目的 研究活血降糖饮对2型糖尿病气阴两虚患者的治疗作用以及对DPP-4活性的影响。 方法 我院门诊及住院2型糖尿病患者共60例分为治疗组和对照组各30例,均给予磷酸西格列订口服治疗,治疗组加用活血降糖饮分别记录年龄性别糖尿病病程治疗前后证候积分空腹及餐后2小时血糖空腹及餐后2小时胰岛素空腹及餐后2小时DPP-4酶活性结果经治疗两组患者证候积分空腹及餐后2小时血糖空腹及餐后2小时DPP-4活性均明显下降,空腹及餐后2小时胰岛素明显升高,差异均有统计学意义(P<0.05,P<0.01);经治疗治疗组证候积分餐后2小时血糖餐后2小时胰岛素餐后2小时DPP-4活性均较对照组降低更加明显,差异有统计学意义(P<0.05,P<0.01);治疗组证候积分餐后2小时血糖餐后2小时胰岛素餐后2小时DPP-4活性治疗前后差值均较对照组明显增加(P<0.05,P<0.01)。结论:活血降糖饮可以改善气阴两虚2型糖尿病患者临床症状,降低空腹和餐后血糖,增加空腹和餐后胰岛素分泌,对于餐后血糖和胰岛素的改善作用较空腹更加明显,其作用可能与降低餐后DPP-4酶活性有关。
Abstract:
Objective:To investigate the therapeutical effect of Huoxue Jiangtang potion on patients of type 2 diabetes with qi-yin deficiency syndrome and its effect on DPP-4activity.Methods:60patients with type 2di- abetes from both the outpatient and inpatient departments were randomized into treatment group and control group with 30case in each.Both groups were orally given sitagliptin phosphate and the cases of the treatment group were additionally given Huoxue Jiangtang potion.The patients age,sex,course of the disease,syndrome integral before and after the treatment,fasting and 2hpostprandial blood glucose,fasting and 2hpostprandial plasma insulin,fasting and postprandial DPP-4enzyme activity were recorded.Results:After the treatment, the syndrome integral,fasting and 2hpostprandial blood glucose as well as fasting and postprandial DPP-4enzyme activity decreased significantly,while the fasting and 2hpostprandial plasma insulin increased greatly,the differences had statistical significance(P<0.05,P<0.01).The syndrome integral,2hpostprandial blood glu- cose,2hpostprandial plasma insulin and 2hpostprandial DPP-4enzyme activity of the treatment group decreased more significantly than those of the control group after the treatment,the differences were statistically significant(P<0.05,P<0.01).The differences before and after the treatment in the syndrome integral,2h postprandial blood glucose,2hpostprandial plasma insulin and 2hpostprandial DPP-4activity of the treatment group increased more significantly than those of the control group and had statistical significance(P<0.05,P<0. 01).Conclusion:Huoxue Jiangtang potion can improve the clinical symptoms of patients of type 2diabetes with qi-yin deficiency,reduce fasting and postprandial blood glucose,increase fasting and postprandial insulin secretion.It is more effective in improving fasting blood glucose and insulin than in postprandial conditions and its effect may be related to reducing postprandial DPP-4enzyme activity.

参考文献/References:

[1]郑筱萸.中药新药临床研究指导原则:试行[M].北京:?中国医药科技出版社,2002.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南 (2013年版)[J].中国糖尿病杂志,2014,24(8):2-42.
[3]周达君,边江红,雷鹏,等.从" 三消" 理论的病理基础看 糖尿病的治疗策略[J].现代中医药,2004,26(3):3-5.
[4]袁敏惠,马小兵,张效科,等.芪萸平糖方联合格华止治?疗2型糖尿病(气阴两虚证)临床研究[J].陕西中医药 大学学报,2016,18(06):63-65.
[5]刘德亮.血瘀和脂毒与糖脂代谢紊乱的关系及活血降糖饮的治疗作用[D].广州:广州中医药大学,2015.
[6]Isbil B N,Gulec G,Ozluk K.Protective effect of centrally-injected glucagon-like peptide-1 on reserpine -induced gastric mucosal lesions in rat:possible mech- anisms[J].Turk J Gastroenterol,2006,17(1):1-6.
[7]Drucker D J,Nauck M A.The incretin system:glucagon-like peptide-1receptor agonists and dipeptidyl peptidase-4inhibitors in type 2diabetes [J].Lancet,2006,368(9548):1696-1705.
[8]Irwin N, Flatt P R.Therapeutic potential for GIP receptor agonists and antagonists[J].Best Pract Res Clin Endocrinol Metab, 2009, 23 (4) :499-512.
[9]Ohnuma K, Hosono O, Dang N H, et al.Dipeptidyl peptidase in autoimmune pathophysiology[J].Adv Clin Chem, 2011, 53 (4) :51-84.
[10]Bengsch B, Seigel B, Flecken T, et al.Human Th17cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26) [J].Immunol,2012,188(11) :5438-5447.
[11]Vilsboll T.On the role of the incretin hormones GIP and GLP-1in the pathogenesis of Type 2diabetes mellitus[J].Dan Med Bull, 2004, 51 (4) :364-370.
[12]Augustyns K, Bal G, Thonus G, et al.The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors[J].Curr Med Chem, 1999, 6 (4) :311-327.
[13]Pala L, Mannucci E, Pezzatini A, et al.Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells[J].Biochem Biophys Res Commun,2003,310(1) :28-31.
[14]Pospisilik J A, Martin J, Doty T, et al.Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozot ocin-induced diabetic rats[J].Diabetes, 2003, 52 (3) :741-750.
[15]Kirino Y, Sato Y, Kamimoto T, et al.Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy:a streptozotocin-induced model using wild-type and DPP4-deficient rats[J].J Endocrinol, 2009, 200 (1) :53-61.
[16]高平, 马晓英, 陈玲, 等.2型糖尿病患者与正常人群体内DPP4活性水平研究.中国现代医药杂志, 2015, 17 (1) :41-43.

相似文献/References:

[1]孟欢欢 刘奕彤 冯建杰 郑明明.中西医结合分期治疗糖尿病肾病临床研究[J].现代中医药,2020,(03):095.[doi:10.13424/j.cnki.mtcm.2020.03.026]

备注/Memo

备注/Memo:
收稿日期:2016-10-05编辑:巩振东
通讯作者:李惠林(1963-),男,博士研究生,教授,主任医师,广东省名中医,从事中医药防治内分泌及代谢性疾病的诊治与研究。E-mail:sztcmLhl@163.com
更新日期/Last Update: 2017-09-15